

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Voriconazole for Injection Product Name: Manufacturer Name: Gland Pharma Limited

Survey No.: 143 - 148, 150 & 151, Near Gandimaisamma Cross Roads D.P. Pally, Quthubullapur Mandal - Ranga Reddy District Address:

Hyderabad, Andhra Pradesh 500 043

India

General Phone Number: +91-40-30510999 +91-40-30510810 General Fax Number:

Emergency Phone Number: +91-40-30510999 (Gland Pharma);

Distributor Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: Customer Service Phone

(847) 550-2300 (888) 386-1300

Number: Health Issues Information: (800) 551-7176 SDS Creation Date: February 18, 2020 SDS Revision Date: September 04, 2020

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:



Signal Word: DANGER

GHS Class: Acute toxicity - Oral, Category 3

Carcinogenicity, Category 2 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 2

Hazard Statements: Toxic if swallowed.

Suspected of causing cancer.

Suspected of damaging fertility or the unborn child.

May cause damage to organs through prolonged or repeated exposure.

Precautionary Statements: Obtain special instructions before use.

Do not handle until all safety precautions have been read and understood.

Do not breathe dust/fume/gas/mist/vapours/spray Wash hands thoroughly after handling.

Do not eat, drink or smoke when using this product. Use personal protective equipment as required. IF exposed or concerned: Get medical advice/attention.

Store locked up

IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.

Rinse mouth. Avoid release to the environment.

Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse

reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Potential Health Effects: Animal studies indicate that this material may cause adverse effects on the liver, the developing fetus.

The most common adverse effects reported with clinical use of voriconazole include visual disturbance, elevations of liver function tests and skin rash. Voriconazole has been associated with photosensitivity skin reactions especially during long term therapy..

Acute Health Effects: This is a medicinal product that may affect body functions. When inside vials the hazard is considered

negligible. May produce slight eye irritation.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Voriconazole	137234-62-9	200 mg/Vial by weight	629-701-5
Hydroxypropyl beta cyclodextrin	128446-35-5	3,200 mg/Vial by weight	

SECTION 4: FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of

the eyes by separating the eyelids with fingers. Get immediate medical attention.

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists. Skin Contact:

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained Inhalation:

personnel. Seek immediate medical attention

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center

immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give

anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Flash Point Method: Not established Not established. Auto Ignition Temperature: Lower Flammable/Explosive Limit: Not established Upper Flammable/Explosive Limit: Not established

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to Fire Fighting Instructions:

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent)

Hazardous Combustion

Byproducts

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion.

2

NFPA Ratings:

Work Practices:

NFPA Health:

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area.

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

listed in Section 8.

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Methods for cleanup: Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After

removal, flush spill area with soap and water to remove trace residue.

SECTION 7: HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes.

Use with adequate ventilation. Use only in accordance with directions

Storage: Keep container tightly closed. Keep container in a cool, dry, well-ventilated area. Protect from light and store at controlled room temperature 20° - 25° C (68° - 77° F). Refer to product packaging

Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist. Hygiene Practices:

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls: General ventilation is sufficient if this product is being used in a controlled medical setting (clinic,

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eve/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended. Hand Protection Description:

Respiratory Protection:

No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

EXPOSURE GUIDELINES

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: A lyophilized powder or cake

White to off-white Color: Not established. **Boiling Point:** Melting Point: Not established. Solubility: Not established. Vapor Density: Not established. Vapor Pressure: Not established. Percent Volatile: Not established. pH: Not established. Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Not reported. Hazardous Polymerization:

Incompatible Materials: Acids, strong oxidizer.

Special Decomposition Products: COx, NOx and emits toxic fumes under fire conditions.

SECTION 11: TOXICOLOGICAL INFORMATION

Eve: May cause slight eye irritation.

Teratogenicity: Animal studies indicate that this material may cause adverse effects on the liver, the developing fetus.

Voriconazole:

RTECS Number: UV9145000

Skin: Dermal - Rat - > 2,000 mg/kg LD50 Oral - Rat - < 300 mg/kg Ingestion:

Suspected human reproductive toxicant Reproductive Toxicity:

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

SECTION 15: REGULATORY INFORMATION

TSCA Inventory Status: Listed
Canada DSL: Listed

<u>Voriconazole</u>:

EC Number: 629-701-5

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 2*
HMIS Fire Hazard: 0
HMIS Reactivity: 0
HMIS Personal Protection: X

SDS Creation Date: February 18, 2020
SDS Revision Date: September 04, 2020

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.